Angelica Welch

Kevin Kalinsky, MD, discusses the current treatment landscape of metastatic HER2-positive breast cancer, the potential for immunotherapy, and what is on the horizon for patients in this population who develop brain metastases.

Brad Kahl, MD, discusses the exciting new advancements on the horizon for the treatment of patients with mantle cell lymphoma.

Daniel J. George, MD, discusses an analysis of RCC patients in the S-TRAC trial with the highest risk of recurrence, and potential prognostic factors of DFS that emerged from the study.

Abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to Lowell L. Hart, MD.

Rashmi K. Murthy, MD, discusses selecting therapy for patients with HER2-positive breast cancer in the curative setting.

Mario Sznol, MD, discusses the latest developments with immunotherapy in metastatic renal cell carcinoma.

Daniel J. George, MD, discusses the findings from Abi Race and the implications they have on clinical trials in prostate cancer moving forward.

David M. Kurtz, MD, PhD, discusses the clinical use of circulating tumor DNA in lymphoma.

Hossein Borghaei, DO, MS, discusses the results of the subgroup analysis of the ongoing CheckMate-227 trial in metastatic non–small cell lung cancer.

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.

Toni K. Choueiri, MD, discusses some of the most significant data presented thus far in 2018 for the treatment of patients with renal cell carcinoma.

Although impressive single-agent data have been seen with agents such as pembrolizumab (Keytruda) versus chemotherapy in a high–PD-L1 population, the combination of PD-L1 inhibitors and chemotherapy may prove to be beneficial in a broader group of patients.

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

Suresh A. Ramalingam, MD, reflects on recent data in small cell lung cancer and what is on the horizon in the landscape.

Talal Hilal, MB, BCh, discusses the findings of a meta-analysis of rituximab maintenance for patients with mantle cell lymphoma (MCL), and the approach to maintenance therapy in patients with MCL.

Hans-Christian Kolberg, MD, discusses ABP 980 and the future of biosimilars in oncology.

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

Michael A. Savin, MD, shares his insight on adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer.

Jacqueline Vuky, MD, discusses the management of metastatic disease and CDK4/6 inhibitors in breast cancer.

Vicky Makker, MD, discusses the updated phase Ib/II results of the combination of pembrolizumab and lenvatinib and the future of endometrial cancer treatment.

Ajai Chari, MD, discusses the addition of daratumumab to carfilzomib and dexamethasone, as well as the potential impact of subcutaneous daratumumab in the treatment of patients with myeloma.

Marina Chiara Garassino, MD, reflects on the first-line approval of osimertinib, recent data with durvalumab, and the promise for combination chemoimmunotherapy in patients with non–small cell lung cancer.

Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

Mitesh J. Borad, MD, discusses liver-directed therapies, systemic therapy, and the management of liver cancer.

Sai-Hong Ignatius Ou, MD, PhD, discusses the current landscapes of ROS1-positive and BRAF-mutant non–small cell lung cancer.

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.